IP Library Granted Patent US 10,118,921
Granted Patent B2
US 10,118,921 · App. 15/535,464 · Granted Nov 6, 2018

Diarylmethylidene piperidine derivatives and their use as delta opoid receptor agnists

Inventors: Bengt Von Mentzer (Göteborg, SE); Ingemar Starke (Göteborg, SE); Peter Brandt (Uppsala, SE)
Assignee: PHARMNOVO AB
C07D417/06A61P25/04C07D401/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,118,921
App. No.
15/535,464
Granted
Nov 6, 2018
Kind
B2
Abstract

A compound of formula I, for use in pain therapy and a pharmaceutical composition comprising said compound.

Claims (14)

1. A compound of formula I

or a pharmaceutically acceptable salt thereof.

2. A method for treating a pain condition in a patient in need thereof comprising administering a therapeutically effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1 to the patient to treat the pain condition.

3. The method according to claim 2 , wherein the pain condition is directed towards acute pain.

4. The method according to claim 2 , wherein the pain condition is directed towards chronic pain.

5. The method according to claim 4 , wherein the pain condition is directed towards chronic joint pain.

6. The method according to claim 4 , wherein the pain condition is directed towards chronic joint pain caused by osteoarthritis or fibromyalgia.

7. A pharmaceutical composition comprising at least a therapeutically effective amount of the compound of the formula I or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient together with a pharmaceutically acceptable carrier.

8. A method for treating pain comprising the step of administering the composition according to claim 7 to a patient in need thereof to treat pain.

9. The method according to claim 8 , wherein the pain is acute or chronic pain.

10. The method according to claim 8 , wherein the pain is chronic joint pain.

11. The method according to claim 8 , wherein composition is administered via at least one of oral, topical, parenteral, intravenous, intramuscular, subcutaneous, intra articular injection, buccal, sublingual, rectal, vaginal, transdermal, nasal or inhalation.

12. The method of claim 8 , wherein the therapeutically effective amount of compound of the formula I or physiologically acceptable salt thereof is from 0.0001-100 mg/kg body weight of the patient.

13. The method of claim 8 , wherein the therapeutically effective amount of compound of the formula I or physiologically acceptable salt thereof is from 0.01-10 mg/kg body weight of the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2018
From: VON MENTZER, BENGT; STARKE, INGEMAR; BRANDT, PETER
To: PHARMNOVO AB
Reel/Frame 047007/0085 →
Priority Claims (1)
SE 1451616 · Dec 19, 2014 · national
Continuity (1)
Related Publication 20170327491A1 · Nov 16, 2017